

Outlook
Thanks to the very strong development during the first half-year and the positive market environment, Eppendorf assumes that it will reach its ambitious growth targets for the entire year and that the company will once again grow faster than the market. As part of the targeted implementation of its company strategy, Eppendorf is continuing to invest heavily in new product and service solutions as well as in digitalization and new business models. This also applies to expansions in production capacity and infrastructure at its German sites in Hamburg, Oldenburg in Holstein, Leipzig and Jülich as well as at the Enfield site, USA. These construction projects represent important efforts in the company's push for further profitable and sustainable growth. In view of the higher costs planned for the infrastructure measures and given comparable exchange rates for the entire year of 2019, the company assumes that EBIT in 2019 will remain at or around the prior-year level of €153.7 million. Source: Eppendorf Press Release from August 20th, 2019, https://corporate.eppendorf.com/en/news-media/newsroom/?layer=/en/press-releases/20082019-eppendorf-ag-with-positive-first-half-year-2019/More News

Pacira BioSciences Acquires GQ Bio
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT
medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Read more …